Thymosin Alpha-1 — Immune Support
The most-studied immune peptide: thymosin-alpha-1 tunes the adaptive immune system, run as a twice-weekly course mirroring its approved clinical cadence.
Why this protocol
thymosin-alpha-1 (Tα1) is a fragment of the thymic protein prothymosin alpha, and it modulates the adaptive immune system — shifting T-cell activity and dampening over-reactive inflammation. It is approved in several countries (as Zadaxin) for hepatitis B and as a vaccine adjuvant, which is where its twice-weekly dose comes from.
It is a mono protocol because the evidence is built around the single agent on a steady twice-weekly schedule. An honesty note worth carrying: while the chronic hepatitis-B use is established, Tα1's most rigorous critical-illness trial (sepsis) was null — so this is immune modulation, not a proven cure for anything.
Convention drawn from the Thymosin Alpha-1 page's cited evidence — the twice-weekly dose is the approved hepatitis-B cadence, applied here for general immune support, which is extrapolation rather than a trial-proven indication. No therapeutic claims.
The regimen
Thymosin Alpha-1
Immune modulation- Dose
- 1.6 mg
- Schedule
- Twice weekly · subcutaneous
- Timing
- Consistent days each week (no circadian data)
Reconstitution calculator
Reconstitution calculator
Calculated for a 1 mL U-100 insulin syringe (100 units/mL).
Units per dose
32
Draw to this mark on a U-100 syringe
- Volume per dose
- 0.32 mL
- Doses per vial
- 6
- Concentration
- 5 mg/mL
One vial lasts
- Daily
- 6 days
- Every other day
- 12 days
- 5×/week
- 8 days
- Large draw (32 units). Double-check the vial size and dose — a mcg/mg mix-up produces values like this.
Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.
Cycle & schedule
Cycle (6–12 weeks)
Tα1 1.6 mg subcutaneously twice weekly — the Zadaxin-approved hepatitis-B cadence — for 6–12 weeks, then assess.
Washout (4–8 weeks)
A 4–8-week break before repeating. Tα1's serum half-life is short (under 3 hours), so it does not accumulate between doses.
Studies behind this protocol
This protocol composes the cited evidence on each peptide's page — see the full bibliography on: Thymosin Alpha-1.
Research use only · Not medical advice · Updated 2026-06-01